CD19 and precursor B-cell acute lymphoblastic leukemia: The current investigation delineates that, relative to the control cohort, the administration of CD19 CAR-T cell therapy, five days subsequent to a combined regimen of cyclophosphamide and fludarabine, markedly disrupts the metabolic pathways in murine models of B-ALL and Burkitt’s lymphoma.